JAYPIRCA®
(pirtobrutinib)
ELI LILLY
HK Reg. No. HK-68865, HK-68866 (08 Oct, 2025)
Composition:3
• Each film-coated tablet contains 50/100 mg of pirtobrutinib
Indication:3
• JAYPIRCA® as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton tyrosine kinase (BTK) inhibitor
• JAYPIRCA® as monotherapy is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have been previously treated with a BTK inhibitor
References
3. EMA. Jaypirca Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/jaypirca-epar-product-information_en.pdf. [Accessed 18 November 2025].
